ABCA1 Gene

ABCA1 Gene - ATP-Binding Cassette Transporter A1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">ABCA1 — ATP-Binding Cassette Transporter A1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ABCA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP-Binding Cassette Transporter A1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q31.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>19</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000165029</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O95477</td></tr>
<tr><td><strong>OMIM</strong></td><td>205400</td></tr>
<tr><td><strong>Protein Class</strong></td><td>ABC transporter, lipid transporter</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ABCA1 Gene - ATP-Binding Cassette Transporter A1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">ABCA1 — ATP-Binding Cassette Transporter A1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ABCA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP-Binding Cassette Transporter A1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q31.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>19</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000165029</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O95477</td></tr>
<tr><td><strong>OMIM</strong></td><td>205400</td></tr>
<tr><td><strong>Protein Class</strong></td><td>ABC transporter, lipid transporter</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ABCA1 (ATP-Binding Cassette Transporter A1) encodes a 2,261 amino acid membrane protein that serves as the primary regulator of cellular cholesterol and phospholipid efflux to apolipoproteins. It belongs to the ABC transporter superfamily and functions as a flippase that translocates cholesterol and phospholipids from the inner to the outer leaflet of the plasma membrane, enabling the formation of nascent high-density lipoprotein (HDL) particles[@taniguchi2017]. In the brain, ABCA1 is essential for maintaining lipid homeostasis in neurons and glia, facilitating [apolipoprotein E](/proteins/apoe) (APOE) lipidation, and modulating amyloid-beta clearance and neuroinflammation[@rehler2021].

ABCA1 is one of the most strongly validated genetic risk factors for late-onset Alzheimer's disease (LOAD). Loss-of-function variants reduce HDL particle formation, impair APOE lipidation, and increase amyloid deposition, while gain-of-function variants are protective[@farrer2005]. This bidirectional evidence makes ABCA1 a high-priority therapeutic target.

Protein Structure

ABCA1 is a full-size ABC transporter with a characteristic architecture:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal transmembrane domain | TM1–TM6 | Forms the channel pore; substrate translocation path |
| Nucleotide-binding domain 1 (NBD1) | Cytoplasmic | ATP binding and hydrolysis; drives conformational change |
| Second transmembrane domain | TM7–TM12 | Complementary pore structure |
| Nucleotide-binding domain 2 (NBD2) | Cytoplasmic | Second ATPase site; critical for transport activity |
| Regulatory domain | C-terminal | Phosphorylation sites; protein-protein interactions |

Transport Mechanism

ABCA1 uses the energy of ATP hydrolysis (at both NBDs) to drive a conformational cycle that translocates lipid molecules across the plasma membrane[@taniguchi2017]:

The rate-limiting step is ADP release from NBD2, which is slower than NBD1 turnover, making the transporter function as a "power stroke" motor.

Normal Function

Cholesterol Efflux

ABCA1 is the rate-limiting step in the reverse cholesterol transport pathway[@taniguchi2017]:

• Cholesterol efflux: Exports excess cellular cholesterol to lipid-poor APOE and APOA-I
• Phospholipid flippase: Translocates phosphatidylcholine and phosphatidylethanolamine
• Nascent HDL formation: One ABCA1 molecule can transfer thousands of lipids per HDL particle
• Cellular cholesterol homeostasis: Prevents foam cell formation in macrophages and other cells

APOE LIPIDATION

The critical function of ABCA1 in the brain is lipidation of [APOE](/proteins/apoe)[@bell2023]:

• APOE is the primary brain apolipoprotein: Synthesized by astrocytes and microglia
• Unlipidated APOE is a poor amyloid-beta receptor and aggregator
• ABCA1-lipidated APOE forms spherical particles (30–50 nm) that:
• Efficiently bind and clear amyloid-beta
• Prevent APOE aggregation
• Promote microglial Aβ phagocytosis
• Support synaptic protection

Astrocyte and Microglial Functions

ABCA1 is highly expressed in astrocytes and microglia, where it supports:

• Astrocytic lipid metabolism: Lipid secretion for neuronal support
• Microglial cholesterol efflux: Prevents foam cell formation in the brain
• Myelin maintenance: Supports oligodendrocyte function and myelination[@berciano2022]
• Synaptic lipid remodeling: Provides lipids for synaptic membrane maintenance

Disease Associations

Alzheimer's Disease

ABCA1 is among the strongest genetic modifiers of AD risk[@farrer2005]:

Genetic Evidence:

• T939Q variant (rs2230808): Reduced HDL; associated with increased AD risk (OR ~1.3)
• R219K variant (rs2066714): Associated with modified AD risk depending on [APOE](/proteins/apoe) background
• Rare loss-of-function variants: Enriched in early-onset AD cases
• GWAS signals: ABCA1 locus shows genome-wide significant association with CSF Aβ42 levels[@wolters2022]

• Markedly increased amyloid plaque burden
• Reduced ApoE lipidation
• Impaired learning and memory even before plaque deposition
• Altered ApoE aggregation state

• Reduced ABCA1 increases neuronal Aβ production
• Altered APP trafficking through lipid rafts

• Microglial activation and pro-inflammatory cytokine release
• Impaired clearance of cellular debris
• Chronic neuroinflammation

• APOE ε4 is less efficiently lipidated by ABCA1 compared to ε3/ε2
• Combined ABCA1 risk variants + APOE ε4 synergistically increase AD risk
• Therapeutic enhancement of ABCA1 may be especially beneficial in ε4 carriers

Parkinson's Disease

ABCA1 involvement in PD is emerging through multiple pathways[@chung2021]:

• Alpha-synuclein and cholesterol: α-Synuclein localizes to lipid rafts and its aggregation is influenced by membrane cholesterol content
• Dopaminergic neuron vulnerability: High cholesterol content in dopaminergic neurons may make them particularly sensitive to ABCA1 dysfunction
• Genetic overlap: Some ABCA1 variants show association with PD risk
• Mitochondrial cholesterol: ABCA1-mediated cholesterol trafficking affects mitochondrial membranes and function

Related Neurodegenerative Conditions

• Cerebral amyloid angiopathy (CAA): ABCA1 dysfunction impairs Aβ clearance along perivascular pathways
• Atherosclerosis and stroke: Peripheral ABCA1 dysfunction increases vascular risk, which is a comorbidity with dementia
• Aging: ABCA1 expression declines with age, paralleling reduced lipid metabolism and increased AD risk[@parks2020]

Therapeutic Targeting

ABCA1 Agonists

Several approaches aim to enhance ABCA1 function for AD treatment[@torsvik2024]:

| Compound | Mechanism | Stage | Reference |
|----------|-----------|-------|-----------|
| CS-6253 | ABCA1 agonist (peptidomimetic) | Phase 1 | Ortega 2024 |
| CS-5050 | LXR agonist with CNS penetration | Preclinical | Wang 2015 |
| AzPC | Lysolipid ABCA1 activator | Research | Torsvik 2024 |
| Gemfibrozil | PPARα agonist (indirect ABCA1 upregulation) | Repurposing | Nguyen 2022 |

LXR Agonists

Liver X Receptor (LXR) agonists upregulate ABCA1 transcription and are highly effective in AD mouse models[@wang2015]:

• GW3965: Reduced amyloid pathology in APP/PS1 mice; but peripheral LXR activation causes fatty liver
• Selectivity challenge: Need CNS-penetrant, peripheral-sparing compounds
• Combination therapy: LXR agonists + APOE-targeting approaches

APOE-Targeting Approaches

Since ABCA1's primary function in the brain is APOE lipidation, approaches that enhance lipidation regardless of ABCA1 upregulation are promising:

• Direct APOE lipidation: Synthetic HDL-like particles
• APOE mimetic peptides: Peptides that mimic lipidated APOE function
• Gene therapy: AAV-mediated ABCA1 overexpression in astrocytes

Mutations and Variants

Pathogenic Variants

| Variant | Type | Effect | Association |
|---------|------|--------|-------------|
| R587W | Missense | Reduced cholesterol efflux | FA (familial) |
| Q597H | Missense | Impaired APOE lipidation | Early-onset AD |
| A1046D | Missense | Decreased protein stability | Moderate AD risk |
| T1515M | Missense | Loss of transporter function | AD risk modifier |

Common Polymorphisms

| SNP | Effect | Population Frequency | AD Association |
|-----|--------|---------------------|-----------------|
| R219K (rs2230806) | Increased HDL | ~35% | Reduced risk (protective) |
| I883M (rs414939) | Modest lipid effect | ~15% | Context-dependent |
| V771M (rs2230807) | Minor functional impact | ~25% | Neutral |
| T939Q (rs2230808) | Reduced HDL efflux | ~20% | Increased AD risk |

Epigenetic Regulation

ABCA1 expression is regulated by epigenetic mechanisms[@chen2023]:

• Promoter methylation: Hyper方射
• Histone acetylation: Open chromatin at ABCA1 locus in astrocytes
• MicroRNAs: miR-33 family targets ABCA1 mRNA (therapeutic target)

ABCA1 in Different Cell Types

Neurons

ABCA1 in neurons:

• Maintains cholesterol homeostasis in synaptic membranes
• Supports synaptic vesicle formation and function
• Modulates NMDA receptor trafficking through lipid raft composition
• Deficiency leads to synaptic dysfunction before overt neurodegeneration

Astrocytes

Astrocytes are the primary source of [APOE](/proteins/apoe) in the brain[@hansen2021]:

• ABCA1 expression in astrocytes is induced by LXR activation
• Astrocyte-derived, ABCA1-lipidated APOE particles are the main Aβ clearance vehicles
• ABCA1 dysfunction in astrocytes causes non-cell autonomous neuronal damage

Microglia

Microglial ABCA1[@huang2019]:

• Controls cholesterol efflux during activation
• Regulates inflammatory response through lipid-mediated signaling
• Aβ phagocytosis is impaired when ABCA1 function is reduced
• Modulates TREM2 signaling through lipid availability

Oligodendrocytes

• Supports myelin membrane lipid composition
• Myelin maintenance requires constant lipid turnover
• ABCA1 deficiency leads to age-related myelin abnormalities

Interaction Network

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| APOE | Lipid transfer substrate | Forms nascent HDL; critical for Aβ clearance |
| APOA-I | Alternative substrate | Peripheral HDL formation |
| CLU (Clusterin) | Physical association | Cooperates in Aβ clearance |
| LDLR | Functional interaction | Cholesterol homeostasis coordination |
| ABCG1 | Cooperates in efflux | Cholesterol efflux to HDL |
| LXRα/β | Transcriptional regulation | Upregulated by LXR agonists |
| PPARγ | Transcriptional regulation | Indirect upregulation |
| RXR | Nuclear receptor heterodimer | LXR acts as LXR-RXR heterodimer |
| ABCA1 itself | Dimerization/oligomerization | Full transporter activity requires dimerization |

Research Directions

Current priorities include:

• Developing CNS-penetrant ABCA1 modulators without peripheral side effects
• Understanding cell-type-specific ABCA1 functions in the brain
• Identifying biomarkers for ABCA1-targeted therapy response
• Exploring gene therapy approaches for ABCA1 upregulation
• Epigenetic therapies to restore ABCA1 expression in aging[@parks2020]

Cross-Linking

Related Genes

• [APOE](/genes/apoe) — Primary substrate for ABCA1-lipidated clearance
• [ABCA7](/genes/abca7) — Related ABC transporter, also in AD
• [CLU](/genes/clu) — Clusterin, cooperates with ABCA1 in Aβ clearance
• [LDLR](/genes/ldlr) — Lipid receptor

Related Proteins

• [APOE Protein](/proteins/apoe) — Critical substrate
• [Amyloid-beta](/proteins/amyloid-beta) — Target of ABCA1-mediated clearance
• [TREM2](/proteins/trem2) — Microglial receptor modulated by lipid status

Related Mechanisms

• [Lipid Metabolism in AD](/mechanisms/lipid-metabolism-alzheimers)
• [APOE and Amyloid Clearance](/mechanisms/apoe-amyloid-clearance)
• [Neuroinflammation Pathways](/mechanisms/neuroinflammation-adrenergic)
• [Cholesterol Transport in the Brain](/mechanisms/cholesterol-transport-brain)

Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

Mechanism Map

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: ABCA1/LDLR/SREBF2